S
Sichuan Xieguang Biotechnology
Provides one-stop chemiluminescent immunoassay (CLIA) solutions
About Sichuan Xieguang Biotechnology
Sichuan Xieguang Biotechnology Co., Ltd., which operates under the name C-Luminary Biotech, is a specialized manufacturer of in-vitro diagnostic (IVD) products. The company was established in January 2018 and has since focused on the research, development, production, and sale of diagnostic solutions, primarily for the global clinical diagnostics market. The firm's business model is centered on the production and sale of chemiluminescence immunoassay (CLIA) reagents and the corresponding fully automated analysis instruments. C-Luminary serves clinical users by providing advanced diagnostic tools.
Since its inception, the company has achieved several key milestones, starting with an angel investment round in May 2018. It secured Pre-A financing in September 2020, followed by a Series A round in late 2021 and has continued to attract venture capital backing through multiple subsequent funding stages. Operationally, C-Luminary has developed an extensive product portfolio, with more than 430 reagent products holding NMPA registration in China and CE conformity declarations for the European market. The company's product lines target the detection of autoimmune disorders, allergens, thrombosis, and cytokines. A key offering is the 'Sharay' series of fully automated CLIA analyzers, which are designed for precision and efficiency in clinical labs. The firm controls its value chain by integrating the development of key raw materials through to the final reagent and instrument manufacturing.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jul 2023 | $14M | $55M | Yuansheng BioVenture · 3E Bioventures | ↗ |
Growth signals
Latest recorded traffic for Sichuan Xieguang Biotechnology is 470 monthly website visits, down 26.6% over the last three months. Sichuan Xieguang Biotechnology's team grew 175% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Sichuan Xieguang Biotechnology in its local ecosystem
The Sichuan Xieguang Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Yuansheng BioVenture
3E Bioventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Sichuan Xieguang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Sichuan Xieguang Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









